Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion type Assertion NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_head.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion description "[Subsequently, patients were classified according to their MRD level at time point 1 (TP1), taken at the end of induction treatment (5 weeks), and at TP2 just before the start of consolidation treatment (3 months).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_provenance.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion evidence source_evidence_literature NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_provenance.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion SIO_000772 12036866 NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_provenance.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion wasDerivedFrom befree-20140225 NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_provenance.
- NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_assertion wasGeneratedBy ECO_0000203 NP658733.RAqek-gI8EUlI3UCg7RkGWfaYgLV3b15bK7uAgkwheRLs130_provenance.